BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 33439105)

  • 1. Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
    Sato Y; Qiu J; Hirose T; Miura T; Sato Y; Kohzuki M; Ito O
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G464-G473. PubMed ID: 33439105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Long-Term Exercise on Liver Cyst in Polycystic Liver Disease Model Rats.
    Sato Y; Qiu J; Miura T; Kohzuki M; Ito O
    Med Sci Sports Exerc; 2020 Jun; 52(6):1272-1279. PubMed ID: 31880641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
    PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
    Leonhard WN; Song X; Kanhai AA; Iliuta IA; Bozovic A; Steinberg GR; Peters DJM; Pei Y
    EBioMedicine; 2019 Sep; 47():436-445. PubMed ID: 31473186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease.
    Tonum K; Srimai N; Chabang N; Fongsupa S; Tuchinda P; Torres JA; Weimbs T; Soodvilai S
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells
    Li Z; Ding Q; Ling LP; Wu Y; Meng DX; Li X; Zhang CQ
    World J Gastroenterol; 2018 Feb; 24(7):819-832. PubMed ID: 29467552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease.
    Temmerman F; Chen F; Libbrecht L; Vander Elst I; Windmolders P; Feng Y; Ni Y; De Smedt H; Nevens F; van Pelt J
    World J Gastroenterol; 2017 Aug; 23(30):5499-5507. PubMed ID: 28852309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.
    Takiar V; Nishio S; Seo-Mayer P; King JD; Li H; Zhang L; Karihaloo A; Hallows KR; Somlo S; Caplan MJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2462-7. PubMed ID: 21262823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
    Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
    Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase.
    Pathomthongtaweechai N; Soodvilai S; Chatsudthipong V; Muanprasat C
    Eur J Pharmacol; 2014 Feb; 724():67-76. PubMed ID: 24360935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Exercise Protects against the Progression of Renal Cyst Growth and Dysfunction in Rats with Polycystic Kidney Disease.
    Qiu J; Sato Y; Xu L; Miura T; Kohzuki M; Ito O
    Med Sci Sports Exerc; 2021 Dec; 53(12):2485-2494. PubMed ID: 34310502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
    Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
    Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
    Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.
    Chang MY; Ma TL; Hung CC; Tian YC; Chen YC; Yang CW; Cheng YC
    Sci Rep; 2017 Aug; 7(1):7161. PubMed ID: 28769124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease.
    Oto OA; Atwood DJ; Chaudhary A; He Z; Li AS; Wempe MF; Edelstein CL
    Physiol Rep; 2023 Sep; 11(17):e15776. PubMed ID: 37653564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity.
    Su L; Yuan H; Zhang H; Wang R; Fu K; Yin L; Ren Y; Liu H; Fang Q; Wang J; Guo D
    FEBS Open Bio; 2022 Oct; 12(10):1761-1770. PubMed ID: 35748097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.